Supporting Breakthroughs in Autoimmune Disease Research at Pharmidex
January 19, 2026

Pharmidex is proud to offer comprehensive in vitro and preclinical solutions tailored to autoimmune disease research, helping accelerate the development of novel treatments.


Our expertise spans multiple autoimmune indications including multiple sclerosis, psoriasis, atopic dermatitis, alopecia, colitis, immune response and vitiligo, combining rigorous proof-of-concept studies with integrated pharmacokinetic, pharmacodynamic, biomarkers analysis, histopathological evaluation of relevant organs and tissues, toxicological and bioanalytical endpoints to support fast-track research.


With deep scientific knowledge and flexible study designs, we partner with researchers to deliver translationally relevant data that informs confident decision-making throughout the drug discovery and development pathway.


If your team is advancing immune-modulating therapies, we’d be delighted to discuss how Pharmidex can help support your research.


🌐 www.pharmidex.com

🫁 Supporting Respiratory Drug Discovery at Pharmidex

January 15, 2026
Pharmidex offers a broad range of pre-clinical respiratory disease models to support drug discovery and development across multiple pulmonary indications. Our capabilities include validated models for asthma (acute, chronic and severe/exacerbation), cough, idiopathic pulmonary fibrosis (IPF), acute lung injury/ARDS, respiratory infections, COPD and allergic rhinitis. These models incorporate clinically relevant triggers and well-established positive controls, enabling robust and translational assessment of novel therapeutics. Our integrated respiratory platforms are designed to help accelerate informed decision-making from early research through to advanced pre-clinical development. If you are developing new therapies for respiratory diseases, we would be pleased to discuss how Pharmidex can support your programme. 🌐 www.pharmidex.com

🔬 Toxicology Studies in the UK – Fast, Flexible & Competitive

January 14, 2026
At Pharmidex , we offer In Vivo (Non-GLP & GLP), In Vitro, and Organ-on-Chip toxicology, alongside our full range of non-GLP and GLP toxicology studies delivered in the UK, with quick turnaround times and UK-competitive pricing. Our experienced team supports your programme from study design through delivery, helping you generate high-quality, decision-ready data efficiently and cost-effectively. 📍 UK-based studies ⚡ Rapid timelines 💷 Competitive pricing 🧪 In Vivo (Non-GLP & GLP), In Vitro & Organ-on-Chip toxicology Learn more: www.pharmidex.com

🎓 Pharmidex at RSC BMCS Postgraduate Symposium XIX 🎓

January 8, 2026
We’re pleased to share that Martin Barrett from Pharmidex will be attending the R SC-BMCS Postgraduate Symposium XIX – Biological and Medicinal Chemistry Symposium for Postgraduates. 📅 Thursday 8th January 2026 📍 MIB Building, Manchester Martin will be presenting at the symposium and representing Pharmidex to discuss our services and capabilities in drug discovery and development. He would be delighted to meet and chat with attendees, explore new ideas, and discuss potential collaborations and partnerships. If you’re attending, please come and say hello! 🌐 www.pharmidex.com 🔗 https://www.rscbmcs.org/events/psxix/
More Posts